Surgery Partners Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Surgery Partners in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Surgery Partners stock.
View analyst ratings for Surgery Partners or view top-rated stocks.

Wall Street analysts have given Surgery Partners a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Surgery Partners wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Surgery Partners is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Surgery Partners.

Surgery Partners, Inc. (NASDAQ:SGRY) posted its quarterly earnings results on Wednesday, May, 5th. The company reported ($0.30) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.30). The business earned $512.40 million during the quarter, compared to the consensus estimate of $505.22 million. Surgery Partners had a negative net margin of 5.67% and a negative trailing twelve-month return on equity of 3.68%.
View Surgery Partners' earnings history.

Surgery Partners' stock was trading at $8.86 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SGRY stock has increased by 655.3% and is now trading at $66.92.
View which stocks have been most impacted by COVID-19.

Surgery Partners issued an update on its FY 2021 earnings guidance on Tuesday, June, 1st. The company provided EPS guidance of - for the period. The company issued revenue guidance of $2.20 billion-$2.23 billion, compared to the consensus revenue estimate of $2.23 billion.

7 analysts have issued 12-month price targets for Surgery Partners' shares. Their forecasts range from $17.50 to $61.00. On average, they expect Surgery Partners' share price to reach $32.07 in the next twelve months. This suggests that the stock has a possible downside of 52.1%.
View analysts' price targets for Surgery Partners or view top-rated stocks among Wall Street analysts.

7 employees have rated Surgery Partners CEO Eric Evans on Glassdoor.com. Eric Evans has an approval rating of 86% among Surgery Partners' employees.

Some companies that are related to Surgery Partners include Universal Health Services (UHS), Tenet Healthcare (THC), Community Health Systems (CYH), First Physicians Capital Group (FPCG), SunLink Health Systems (SSY), Ethema Health (GRST), Nobilis Health (HLTH) and Rennova Health (RNVA).
View all of SGRY's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Surgery Partners investors own include Sorrento Therapeutics (SRNE), Rigel Pharmaceuticals (RIGL), Ardelyx (ARDX), Glu Mobile (GLUU), Ocular Therapeutix (OCUL), Sangamo Therapeutics (SGMO), Xilinx (XLNX), Allena Pharmaceuticals (ALNA), Editas Medicine (EDIT) and Maxar Technologies (MAXR).

Surgery Partners trades on the NASDAQ under the ticker symbol "SGRY."

Surgery Partners' stock is owned by a number of retail and institutional investors. Top institutional investors include Clearbridge Investments LLC (6.08%), Price T Rowe Associates Inc. MD (4.55%), BlackRock Inc. (3.27%), Dimensional Fund Advisors LP (2.22%), Victory Capital Management Inc. (1.38%) and Federated Hermes Inc. (1.38%). Company insiders that own Surgery Partners stock include Anthony Taparo, George Goodwin, Jason Eric Evans, Jennifer Baldock, Teresa Deluca and Thomas F Cowhey.
View institutional ownership trends for Surgery Partners.

SGRY stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Bank of Montreal Can, Royce & Associates LP, Renaissance Technologies LLC, Polar Capital Holdings Plc, Citigroup Inc., Connacht Asset Management LP, and Clearbridge Investments LLC. Company insiders that have sold Surgery Partners company stock in the last year include Anthony Taparo, George Goodwin, Jennifer Baldock, Teresa Deluca, and Thomas F Cowhey.
View insider buying and selling activity for Surgery Partners or view top insider-selling stocks.

SGRY stock was acquired by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Victory Capital Management Inc., Federated Hermes Inc., Morgan Stanley, BlackRock Inc., Lisanti Capital Growth LLC, Goldman Sachs Group Inc., and Geode Capital Management LLC. Company insiders that have bought Surgery Partners stock in the last two years include Jason Eric Evans, and Teresa Deluca.
View insider buying and selling activity for Surgery Partners or or view top insider-buying stocks.

Shares of SGRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SGRY stock can currently be purchased for approximately $66.92.

Surgery Partners has a market capitalization of $4.01 billion and generates $1.86 billion in revenue each year. The company earns $-116,100,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis.

Surgery Partners employs 10,800 workers across the globe.

The official website for Surgery Partners is www.surgerypartners.com.

Surgery Partners is headquartered at 310 Seven Springs Way Suite 500, Brentwood TN, 37027.

Surgery Partners' mailing address is 310 Seven Springs Way Suite 500, Brentwood TN, 37027. The company can be reached via phone at 615-234-5900 or via email at [email protected]